IBDEI0PF ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11424,0)
 ;;=93784^^45^548^2^^^^1
 ;;^UTILITY(U,$J,358.3,11424,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11424,1,2,0)
 ;;=2^Amb BP Monitor 24+ hrs,Intrp & Rpt
 ;;^UTILITY(U,$J,358.3,11424,1,3,0)
 ;;=3^93784
 ;;^UTILITY(U,$J,358.3,11425,0)
 ;;=93786^^45^548^3^^^^1
 ;;^UTILITY(U,$J,358.3,11425,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11425,1,2,0)
 ;;=2^Amb BP Monitor 24+ hrs,Rpt Only
 ;;^UTILITY(U,$J,358.3,11425,1,3,0)
 ;;=3^93786
 ;;^UTILITY(U,$J,358.3,11426,0)
 ;;=93788^^45^548^1^^^^1
 ;;^UTILITY(U,$J,358.3,11426,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11426,1,2,0)
 ;;=2^Amb BP Analysis & Rpt
 ;;^UTILITY(U,$J,358.3,11426,1,3,0)
 ;;=3^93788
 ;;^UTILITY(U,$J,358.3,11427,0)
 ;;=93790^^45^548^4^^^^1
 ;;^UTILITY(U,$J,358.3,11427,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11427,1,2,0)
 ;;=2^Amb BP Review,Intrp & Rpt
 ;;^UTILITY(U,$J,358.3,11427,1,3,0)
 ;;=3^93790
 ;;^UTILITY(U,$J,358.3,11428,0)
 ;;=93770^^45^548^5^^^^1
 ;;^UTILITY(U,$J,358.3,11428,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11428,1,2,0)
 ;;=2^Measure Venous Pressure
 ;;^UTILITY(U,$J,358.3,11428,1,3,0)
 ;;=3^93770
 ;;^UTILITY(U,$J,358.3,11429,0)
 ;;=J0636^^45^549^1^^^^1
 ;;^UTILITY(U,$J,358.3,11429,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11429,1,2,0)
 ;;=2^Calcitriol per 0.1 MCG
 ;;^UTILITY(U,$J,358.3,11429,1,3,0)
 ;;=3^J0636
 ;;^UTILITY(U,$J,358.3,11430,0)
 ;;=J0713^^45^549^2^^^^1
 ;;^UTILITY(U,$J,358.3,11430,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11430,1,2,0)
 ;;=2^Ceftazidime per 500 MG
 ;;^UTILITY(U,$J,358.3,11430,1,3,0)
 ;;=3^J0713
 ;;^UTILITY(U,$J,358.3,11431,0)
 ;;=J1160^^45^549^5^^^^1
 ;;^UTILITY(U,$J,358.3,11431,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11431,1,2,0)
 ;;=2^Digoxin up to 0.5 MG
 ;;^UTILITY(U,$J,358.3,11431,1,3,0)
 ;;=3^J1160
 ;;^UTILITY(U,$J,358.3,11432,0)
 ;;=Q0138^^45^549^9^^^^1
 ;;^UTILITY(U,$J,358.3,11432,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11432,1,2,0)
 ;;=2^Ferumoxytol,Non-ESRD,1 MG
 ;;^UTILITY(U,$J,358.3,11432,1,3,0)
 ;;=3^Q0138
 ;;^UTILITY(U,$J,358.3,11433,0)
 ;;=Q0139^^45^549^8^^^^1
 ;;^UTILITY(U,$J,358.3,11433,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11433,1,2,0)
 ;;=2^Ferumoxytol,ESRD Use,1 MG
 ;;^UTILITY(U,$J,358.3,11433,1,3,0)
 ;;=3^Q0139
 ;;^UTILITY(U,$J,358.3,11434,0)
 ;;=J1580^^45^549^10^^^^1
 ;;^UTILITY(U,$J,358.3,11434,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11434,1,2,0)
 ;;=2^Garamycin Gentamicin up to 80 MG
 ;;^UTILITY(U,$J,358.3,11434,1,3,0)
 ;;=3^J1580
 ;;^UTILITY(U,$J,358.3,11435,0)
 ;;=J1644^^45^549^12^^^^1
 ;;^UTILITY(U,$J,358.3,11435,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11435,1,2,0)
 ;;=2^Heparin Sodium per 1000 Units
 ;;^UTILITY(U,$J,358.3,11435,1,3,0)
 ;;=3^J1644
 ;;^UTILITY(U,$J,358.3,11436,0)
 ;;=96374^^45^549^13^^^^1
 ;;^UTILITY(U,$J,358.3,11436,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11436,1,2,0)
 ;;=2^IV Push,Ther/Proph/Diag
 ;;^UTILITY(U,$J,358.3,11436,1,3,0)
 ;;=3^96374
 ;;^UTILITY(U,$J,358.3,11437,0)
 ;;=J1750^^45^549^14^^^^1
 ;;^UTILITY(U,$J,358.3,11437,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11437,1,2,0)
 ;;=2^Iron Dextran 50 MG
 ;;^UTILITY(U,$J,358.3,11437,1,3,0)
 ;;=3^J1750
 ;;^UTILITY(U,$J,358.3,11438,0)
 ;;=B4189^^45^549^15^^^^1
 ;;^UTILITY(U,$J,358.3,11438,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,11438,1,2,0)
 ;;=2^Parenteral NutrSol 10-51 g Protein
 ;;^UTILITY(U,$J,358.3,11438,1,3,0)
 ;;=3^B4189
